Search

everythinglearnresearchcommunity

for

Search:↓

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

The new antibody, TYHF-1, specifically targets certain hair-related structures.

Cedrol may help treat inflammatory bowel disease by improving gut health and function.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.

Drospirenone can hide symptoms of certain hormonal disorders, complicating diagnosis.

Doxycycline can effectively treat hair loss caused by EGFR inhibitors.

HAC and BAC improve skin targeting and reduce diffusion without causing irritation.

A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.

Cyclosporin A, a drug, reduces TGF-β2 expression in skin cells, potentially causing excessive hair growth through a process involving the calcineurin/NFAT pathway.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

A prostate cancer drug can lower the levels of a protein that the coronavirus uses to enter lung cells.

New chemical compounds were made that effectively block an enzyme linked to prostate growth.

Isotretinoin can raise CPK levels, so patients need monitoring, especially before surgery.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.

Tofacitinib treatment for hair loss may worsen acne.

Long-term use of calcineurin inhibitors in transplant patients can cause hormone issues that can be managed with proper care.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Retinoids can cause skin issues and hair loss due to their effects on cell membranes.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.

Men with early-onset hair loss are less responsive to bromocriptine's heart and metabolism benefits.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Researchers created a mouse model for Cushing's syndrome to study glucocorticoid excess and potential treatments.